This marks the first dedicated transcatheter heart valve approved for high-risk patients with symptomatic severe AR.

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green ...

Background Transcatheter aortic valve replacement (TAVR) has already been recommended for some high-risk patients with aortic ...

Aortic insufficiency is a potentially severe condition that affects the heart’s ability to pump blood. There are many possible causes for this condition. Aortic insufficiency is a form of heart valve ...

JenaValve's Trilogy System, FDA-approved for severe AR, offers secure anchoring without calcium. It is a breakthrough for ...

The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition ...

The FDA approved the Trilogy Transcatheter Heart Valve System for the treatment of symptomatic severe aortic regurgitation, ...

The FDA PMA for JenaValve's Trilogy device for TAVR-AR comes months after a court struck down Edwards Lifesciences attempt to ...

PARIS -- The early commercial experience with transcatheter aortic valve replacement (TAVR or TAVI) for severe aortic regurgitation appeared promising, though device size issues and conduction ...

SAN FRANCISCO — Among patients with symptomatic, severe native aortic regurgitation at high surgical risk, the JenaValve Trilogy transcatheter heart valve system (JenaValve Technology) met its primary ...

Atrial fibrillation (AF) was present in 1 in 6 patients with chronic aortic regurgitation — either moderate-to-severe or severe — and was independently associated with an increased risk for mortality ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — A novel dicrotic notch index identified hemodynamically significant paravalvular aortic ...